CLINICAL PROFILE OF PATIENTS WITH MULTIPLE MYELOMA TREATED AT A NEW ONCOLOGY CENTER: EVIDENCE OF ADVANCED-STAGE DIAGNOSIS
- 1Instituto de Oncologia Ciências Médicas (IONCM-CMMG), Belo Horizonte, MG, Brasil
Abstract
Background: Multiple myeloma remains a significant diagnostic challenge due to its often nonspecific initial clinical manifestations, such as bone pain, anemia, and fatigue. Delayed recognition favors the development of disease-related complications, particularly renal impairment and bone lesions, with a negative impact on morbidity and prognosis. Characterizing the clinical profile of patients at diagnosis may help identify weaknesses along the care pathway and support continuing education strategies targeted at Primary Care, favoring timely referral for specialized evaluation. Aim: To describe the clinical and epidemiological profile of patients with multiple myeloma treated during the first months of operation of a new oncology center, assessing markers of advanced disease at diagnosis and discussing possible implications related to delayed referral for hematological evaluation. Methods: This is a single-center, observational, retrospective, longitudinal, and descriptive study based on the Hospital Cancer Registry of an Oncology Center. Patients diagnosed with multiple myeloma and registered between November 2024 and July 2025 were included. Demographic characteristics, comorbidities, the interval between the first consultation and diagnosis, time to treatment initiation, and staging according to the International Staging System (ISS) were assessed. Data were analyzed using descriptive statistics. Results: A total of 116 patients were included, 61 (52.6%) of whom were male. Mean age was 69.5 years (median 70.7; range 47.4–90.5 years). The most frequent comorbidities were hypertension (42%), cardiac arrhythmias (42%), diabetes mellitus (15%), chronic kidney disease (14%), and heart failure (4.3%). Among risk factors, 18% were smokers, 20% were alcohol users, and 14% had a family history of cancer. The mean interval between the first consultation and diagnosis was 63.3 days, and between diagnosis and treatment initiation, 72.5 days. Regarding staging, 22% of patients presented with ISS I, 31% with ISS II, and 38% with ISS III at diagnosis. Discussion: A high proportion of patients presented with advanced disease at diagnosis, associated with a substantial comorbidity burden. Although this profile may partly reflect the tertiary nature of the service, the high frequency of patients classified as ISS III is consistent with delayed referral for specialized evaluation. These findings underscore the need to strengthen the multiple myeloma care pathway, particularly through primary care training in the recognition of warning signs and the establishment of more agile referral pathways to hematological evaluation. Conclusion: Patients with multiple myeloma treated during the first months of the service's operation showed a high frequency of advanced disease at diagnosis and a substantial comorbidity burden. This profile is consistent with delayed referral for specialized evaluation and reinforces the need to strengthen integration between primary care and hematology, promoting early disease recognition and reducing complications arising from diagnosis at advanced stages.
Related
- The role of information and consent forms in patients’ decision-making regarding participation in oncology clinical trials
- From Global Evidence to Saudi Practice: A Structured Evidence Map of the Diagnosis, Molecular Targets, and Therapeutic Strategies of Multiple Sclerosis in the Kingdom of Saudi Arabia.
- Choosing Between Anti-TROP2 ADCs in Advanced Breast Cancer Without Head-to-Head Evidence: A Practical Evidence-Informed Decision Framework Endorsed by the Polish Society of Clinical Oncology.
- OncoAgentic-RAG: An evidence-grounded multi-agent hybrid retrieval-augmented system for patient-centric clinical oncology question answering
- Research progress and clinical translation prospects of multiple urinary biomarkers in non-invasive diagnosis of urothelial carcinoma
BibTeX
@article{anastacio2026clinical,
title = {{CLINICAL PROFILE OF PATIENTS WITH MULTIPLE MYELOMA TREATED AT A NEW ONCOLOGY CENTER: EVIDENCE OF ADVANCED-STAGE DIAGNOSIS}},
author = {Lucas de Barros ANASTACIO and Peterson Cardoso GONTIJO and Pedro Alcântara Botelho MACHADO and Marcia Torresan DELAMAIN},
journal = {Hematology, Transfusion and Cell Therapy},
year = {2026},
month = oct,
doi = {10.1016/j.htct.2026.107850},
url = {https://doi.org/10.1016/j.htct.2026.107850},
note = {CC BY},
}
RIS
TY - JOUR
TI - CLINICAL PROFILE OF PATIENTS WITH MULTIPLE MYELOMA TREATED AT A NEW ONCOLOGY CENTER: EVIDENCE OF ADVANCED-STAGE DIAGNOSIS
AU - Lucas de Barros ANASTACIO
AU - Peterson Cardoso GONTIJO
AU - Pedro Alcântara Botelho MACHADO
AU - Marcia Torresan DELAMAIN
PY - 2026
DA - 2026/10/23
JO - Hematology, Transfusion and Cell Therapy
DO - 10.1016/j.htct.2026.107850
UR - https://doi.org/10.1016/j.htct.2026.107850
AB - Background: Multiple myeloma remains a significant diagnostic challenge due to its often nonspecific initial clinical manifestations, such as bone pain, anemia, and fatigue. Delayed recognition favors the development of disease-related complications, particularly renal impairment and bone lesions, with a negative impact on morbidity and prognosis. Characterizing the clinical profile of patients at diagnosis may help identify weaknesses along the care pathway and support continuing education strategies targeted at Primary Care, favoring timely referral for specialized evaluation. Aim: To describe the clinical and epidemiological profile of patients with multiple myeloma treated during the first months of operation of a new oncology center, assessing markers of advanced disease at diagnosis and discussing possible implications related to delayed referral for hematological evaluation. Methods: This is a single-center, observational, retrospective, longitudinal, and descriptive study based on the Hospital Cancer Registry of an Oncology Center. Patients diagnosed with multiple myeloma and registered between November 2024 and July 2025 were included. Demographic characteristics, comorbidities, the interval between the first consultation and diagnosis, time to treatment initiation, and staging according to the International Staging System (ISS) were assessed. Data were analyzed using descriptive statistics. Results: A total of 116 patients were included, 61 (52.6%) of whom were male. Mean age was 69.5 years (median 70.7; range 47.4–90.5 years). The most frequent comorbidities were hypertension (42%), cardiac arrhythmias (42%), diabetes mellitus (15%), chronic kidney disease (14%), and heart failure (4.3%). Among risk factors, 18% were smokers, 20% were alcohol users, and 14% had a family history of cancer. The mean interval between the first consultation and diagnosis was 63.3 days, and between diagnosis and treatment initiation, 72.5 days. Regarding staging, 22% of patients presented with ISS I, 31% with ISS II, and 38% with ISS III at diagnosis. Discussion: A high proportion of patients presented with advanced disease at diagnosis, associated with a substantial comorbidity burden. Although this profile may partly reflect the tertiary nature of the service, the high frequency of patients classified as ISS III is consistent with delayed referral for specialized evaluation. These findings underscore the need to strengthen the multiple myeloma care pathway, particularly through primary care training in the recognition of warning signs and the establishment of more agile referral pathways to hematological evaluation. Conclusion: Patients with multiple myeloma treated during the first months of the service's operation showed a high frequency of advanced disease at diagnosis and a substantial comorbidity burden. This profile is consistent with delayed referral for specialized evaluation and reinforces the need to strengthen integration between primary care and hematology, promoting early disease recognition and reducing complications arising from diagnosis at advanced stages.
SN - 2531-1379
SN - 2531-1387
ER -